Pliant Therapeutics, Inc. — Q3 2023 Form 10-Q
Business context and reporting period. Clinical-stage biopharmaceutical company developing fibrosis therapies, with bexotegrast as its lead candidate. The filing covers the quarter and nine months ended September 30, 2023; financial statements are unaudited. Pliant has no approved products and no product-sales revenue.
Key financial metrics
Amounts below are in millions of dollars, except per-share data.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0.0 | $1.5 | $1.6 | $7.7 |
| Research and development expense | $32.3 | $24.6 | $94.6 | $71.8 |
| General and administrative expense | $15.3 | $8.8 | $44.1 | $25.7 |
| Net loss | $41.5 | $30.6 | $120.2 | $88.3 |
| Net loss per share, basic and diluted | $0.70 | $0.65 | $2.06 | $2.22 |
| Net cash used in operating activities | — | $91.3 | $63.4 |
At September 30, 2023, cash and cash equivalents were $57.7 million and short-term investments were $465.9 million, totaling $523.6 million. Total assets were $540.5 million; current liabilities were $27.4 million; stockholders’ equity was $503.0 million. Long-term debt was $10.0 million, with a stated effective interest rate of 12.69%. The Oxford loan is secured by substantially all current and future assets, subject to the agreement’s terms.
For the nine months, financing provided $274.2 million of cash, primarily reflecting the January 2023 public offering. Investing activities used $158.9 million, largely reflecting investment purchases net of maturities; this is not equivalent to operating cash burn. No operating margin is meaningful for this development-stage company without product sales.
Material changes versus comparable periods
- Revenue fell by $1.5 million in Q3 and $6.1 million for the nine-month period, primarily because the Novartis collaboration ended in April 2023. No collaboration revenue was recorded in Q3 2023.
- Q3 R&D expense increased $7.7 million, mainly from personnel costs, clinical-trial activity and manufacturing for IPF clinical supply. Nine-month R&D expense rose $22.8 million, including increased IPF Phase 2b trial and manufacturing costs.
- Q3 G&A expense increased $6.5 million; the nine-month increase was $18.4 million. The company cited higher employee-related costs, stock-based compensation and professional services.
- Net loss increased $10.9 million in Q3 and $32.0 million for the nine months. Higher investment income partially offset operating losses: nine-month interest and other income was $17.8 million versus $2.0 million in 2022.
- Operating cash use increased $27.9 million year over year for the nine months. Stock-based compensation was $35.3 million, compared with $11.7 million in the prior-year period.
- In January 2023, Pliant issued 9.6 million shares and reported approximately $269.5 million of net proceeds, increasing shares outstanding and providing substantial liquidity.
Outlook, developments and risks
- Management expects existing cash, cash equivalents and short-term investments to fund projected operating requirements into the second half of 2026. It cautions that estimates depend on assumptions and that additional capital will be needed to complete clinical development; spending or trial changes could shorten the runway.
- Management expects R&D and G&A expenses to rise as programs advance and the company builds operations. No product-sales revenue is expected in the near term.
- BEACON-IPF, a Phase 2b bexotegrast trial, was enrolling and planned to include approximately 270 patients. Management expected interim 12-week data from the 320 mg INTEGRIS-PSC cohort in Q1 2024 and 24-week data in mid-2024. The filing reported positive 12-week Phase 2a PSC results and an October DSMB recommendation to continue the trial without modification; these are company-reported clinical updates, not financial results.
- PLN-101095 Phase 1 enrollment was ongoing. A first-in-human filing for the preclinical muscular dystrophy candidate PLN-101325 was expected in Q1 2024.
- Novartis terminated its collaboration, effective April 18, 2023; PLN-1474 rights reverted to Pliant, while future Novartis milestones, royalties and R&D funding ended.
- A new approximately 100,904-square-foot South San Francisco lease was signed in September 2023. Future lease payments are approximately $43.7 million over an expected seven-year term, beginning after tenant improvements, with payments expected to start in Q3 2024; a $1.4 million letter of credit is required. The lease was not yet recognized as a lease asset or liability at quarter-end.
- Key risks include clinical efficacy, safety and enrollment uncertainty; reliance on third parties and a sole-source bexotegrast manufacturer, including suppliers in China; competition; intellectual-property and regulatory risks; and dependence on future financing. The company reported no material legal proceedings and no off-balance-sheet arrangements. Disclosure controls were considered effective at a reasonable assurance level.
Important facts for investors to verify
- Whether clinical trial enrollment, data timing and reported safety or efficacy findings match subsequent company and regulatory disclosures.
- Whether the stated cash runway into the second half of 2026 remains supportable as trial, manufacturing, lease and operating costs evolve.
- The impact of the lost Novartis funding and whether Pliant secures a new collaboration or raises additional capital, including potential dilution.
- The full Oxford loan terms, interest-rate exposure, collateral and repayment schedule, and the timing and accounting impact of the new lease.
- Future R&D and G&A spending, operating cash use, stock-based compensation and share-count growth.